Humedix, an aesthetics and pharmaceutical company under the Huons Group, said it has received final certification from the Ministry of Food and Drug Safety confirming its manufacturing facility meets Good Manufacturing Practice (GMP) standards for biopharmaceutical contract manufacturing, or CMO — production carried out on behalf of other drugmakers. The certification covers a facility for producing finished recombinant biologic drugs. Humedix said the approval extends its established quality and manufacturing system — previously built around chemical drugs and aesthetic products — into the biopharmaceutical sector. With the certification, Humedix said it plans to handle finished-product manufacturing for "human-derived hyaluronidase," a biopharmaceutical currently in development by its affiliate, Huons Lab. The company said the certification positions it to begin commercial production as soon as Huons Lab receives regulatory approval for the drug, which the affiliate is targeting for the second half of this year. Humedix said the newly certified facility has large-scale production